stoxline Quote Chart Rank Option Currency Glossary
  
Ocuphire Pharma, Inc. (OCUP)
2.05  0.11 (5.67%)    07-17 16:00
Open: 1.98
High: 2.08
Volume: 180,141
  
Pre. Close: 1.94
Low: 1.98
Market Cap: 53(M)
Technical analysis
2024-07-17 5:29:21 PM
Short term     
Mid term     
Targets 6-month :  2.48 1-year :  2.9
Resists First :  2.12 Second :  2.48
Pivot price 1.69
Supports First :  1.74 Second :  1.5
MAs MA(5) :  1.96 MA(20) :  1.66
MA(100) :  1.84 MA(250) :  2.69
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  82.1 D(3) :  86.7
RSI RSI(14): 67.9
52-week High :  4.5 Low :  1.5
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ OCUP ] has closed below upper band by 5.7%. Bollinger Bands are 82.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 2.08 - 2.09 2.09 - 2.1
Low: 1.96 - 1.97 1.97 - 1.98
Close: 2.03 - 2.05 2.05 - 2.06
Company Description

Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical trial for dim light or night vision disturbances; and Phase 2b clinical trial for pharmacologically induced mydriasis, as well as that has completed Phase 2 VEGA-1 trial for presbyopia. The company also develops APX3330, a twice-a-day oral tablet to target pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy and diabetic macular edema; and APX2009 and APX2014 second generation preclinical product candidates and analogs of APX3330. Ocuphire Pharma, Inc. is headquartered in Farmington Hills, Michigan.

Headline News

Wed, 17 Jul 2024
OCUP (Ocuphire Pharma) Float Percentage Of Total Shares Out - GuruFocus.com

Fri, 12 Jul 2024
Companies Like Ocuphire Pharma (NASDAQ:OCUP) Are In A Position To Invest In Growth - Simply Wall St

Wed, 10 Jul 2024
Ocuphire Pharma to Highlight APX3330 for Diabetic Retinopathy at Two Scientific Meetings in July - GlobeNewswire

Thu, 06 Jun 2024
Ocuphire Pharma to present APX3330 clinical updates - Investing.com

Sun, 12 May 2024
Ocuphire Pharma Gambles on Cash-Pay Strategy for RYZUMVI: Is It a Path to Profit or a Financial Pitfall? - TipRanks

Fri, 10 May 2024
Ocuphire Pharma Announces Financial Results for First Quarter 2024 and Provides Corporate Update - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 26 (M)
Shares Float 24 (M)
Held by Insiders 7.4 (%)
Held by Institutions 13 (%)
Shares Short 1,210 (K)
Shares Short P.Month 1,320 (K)
Stock Financials
EPS -0.47
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.84
Profit Margin -59.5 %
Operating Margin -450.5 %
Return on Assets (ttm) -15.7 %
Return on Equity (ttm) -25.9 %
Qtrly Rev. Growth -2.3 %
Gross Profit (p.s.) 0
Sales Per Share 0.73
EBITDA (p.s.) -0.47
Qtrly Earnings Growth 0 %
Operating Cash Flow -3 (M)
Levered Free Cash Flow -1 (M)
Stock Valuations
PE Ratio -4.37
PEG Ratio 0
Price to Book value 1.11
Price to Sales 2.79
Price to Cash Flow -16.71
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android